International Biobanking for Lung Cancer and COPD as the Future Resource for Clinical Protein Research
(2013) In EuPA Open Proteomics 1. p.3-7- Abstract
- Characterized tissue with pathological grading and blood samples as well as other biofluids forms the basis for all biobanks as a resource in modern life science. Biobanks are accessed to measure biological components that can be used to monitor the status of health and disease in individual samples and population groups. The biomarker diagnostics area, predicting drug efficacy, stratification of patient groups, can benefit from the continuous qualitative developments, where Proteomics can make a difference in lung cancer and COPD. This in turn can provide key treasures to novel drugs for personalized medicine in the future.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3411874
- author
- Fehniger, Thomas LU ; Végvári, Ákos LU ; Rezeli, Melinda LU ; Döme, Balázs ; Timár, József and Marko-Varga, György LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Lung Cancer, COPD, Biobank, Pathology
- in
- EuPA Open Proteomics
- volume
- 1
- pages
- 3 - 7
- publisher
- Elsevier
- external identifiers
-
- scopus:84884583780
- ISSN
- 2212-9685
- DOI
- 10.1016/j.euprot.2013.04.001
- language
- English
- LU publication?
- yes
- id
- d53fe5c9-0a6c-4b85-9b80-e612707ddaf7 (old id 3411874)
- date added to LUP
- 2016-04-01 13:49:09
- date last changed
- 2023-09-03 05:33:50
@article{d53fe5c9-0a6c-4b85-9b80-e612707ddaf7, abstract = {{Characterized tissue with pathological grading and blood samples as well as other biofluids forms the basis for all biobanks as a resource in modern life science. Biobanks are accessed to measure biological components that can be used to monitor the status of health and disease in individual samples and population groups. The biomarker diagnostics area, predicting drug efficacy, stratification of patient groups, can benefit from the continuous qualitative developments, where Proteomics can make a difference in lung cancer and COPD. This in turn can provide key treasures to novel drugs for personalized medicine in the future.}}, author = {{Fehniger, Thomas and Végvári, Ákos and Rezeli, Melinda and Döme, Balázs and Timár, József and Marko-Varga, György}}, issn = {{2212-9685}}, keywords = {{Lung Cancer; COPD; Biobank; Pathology}}, language = {{eng}}, pages = {{3--7}}, publisher = {{Elsevier}}, series = {{EuPA Open Proteomics}}, title = {{International Biobanking for Lung Cancer and COPD as the Future Resource for Clinical Protein Research}}, url = {{http://dx.doi.org/10.1016/j.euprot.2013.04.001}}, doi = {{10.1016/j.euprot.2013.04.001}}, volume = {{1}}, year = {{2013}}, }